Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Xuanwu Hospital, Beijing
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06607900CT.gov hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple System Atrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Huc-Msc-Sev-001 Nasal Drops (this asset) | Xuanwu Hospital, Beijing | P1 | CC · 43 |
| Droxidopa | Loma Linda University | P3 | BB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BB |
| Ioflupane | GE Healthcare | P3 | B |
| Ath-434 | Alterity Therapeutics | P2 | B |
| Riluzole | King's College London | P3 | B |
| Exidavnemab | BioArctic AB | P2 | CCC |
| Fipamezole | Juvantia Pharma Ltd | P2 | CCC |
| Midodrine | Vanderbilt University Medical Center | P1 | CCC |
+31 more in the Multiple System Atrophy cohort
Other indications for Huc-Msc-Sev-001 Nasal Drops
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lewy Body Dementia | — | P1 | CC · 43 |
| Frontotemporal Dementia | — | P1 | CC · 43 |
| Amyotrophic Lateral Sclerosis | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Huc-Msc-Sev-001 Nasal Drops in Multiple System Atrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/huc-msc-sev-001-nasal-drops-multiple-system-atrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →